


**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Original) A compound of formula (I):



or a salt or solvate thereof, wherein:


R<sup>1</sup> is -<sup>11</sup>CH<sub>2</sub>R<sup>5</sup> or [<sup>18</sup>F]-C<sub>1-4</sub> fluoroalkyl wherein R<sup>5</sup> is hydrogen or C<sub>1-4</sub> alkyl;

R<sup>2</sup> is hydrogen or C<sub>1-4</sub> alkyl;

R<sup>3</sup> is halo; and


R<sup>4</sup> is halo, C<sub>1-4</sub> alkylthio, or C<sub>1-4</sub> alkyl.

2. (Original) A compound according to claim 1 of formula (Ia) :



or a salt or solvate thereof, wherein  $R^1$ ,  $R^2$ ,  $R^3$ , and  $R^4$  are as defined in claim 1.

3. (Previously presented) A compound according to claim 1 of formula (Ib):




or a salt or solvate thereof, wherein:

$R^4$  is  $C_{1-4}$  alkylthio;

$R^1$  is either  $-^{11}CH_3$ ,  $-^{11}CH_2CH_3$ , or  $-^{11}CH_2CH_2CH_3$  or  $R^1$  is  $-CH_2^{18}F$ ,  $-CH_2CH_2^{18}F$ , or  $-CH_2CH_2CH_2^{18}F$ .

4. (Original) A compound of formula (Ic):



or a salt or solvate thereof, wherein:

$R^{1c}$  is  $C_{1-4}$  alkyl or  $C_{1-4}$  haloalkyl;

$R^{2c}$  is hydrogen or  $C_{1-4}$  alkyl;

$R^{3c}$  is radioiodine (suitably  $^{123}I$ ,  $^{124}I$ ,  $^{125}I$ , or  $^{131}I$ ); and

$R^{4c}$  is halo,  $C_{1-4}$  alkylthio, or  $C_{1-4}$  alkyl.

5. (Previously presented) A compound according to claim 1, selected from:

Appl. No. 10/522,204  
Amdt. Dated July 19, 2007  
Reply to Office action of February 6, 2007

(N-(2-chloro-5-(methylthio)phenyl)-N'-(3-methylthio)phenyl)-N'-[N-methyl-<sup>11</sup>C]-methylguanidine; and

(N-(2-chloro-5-(methylthio)phenyl)-N'-(3-methylthio)phenyl)-N'-[<sup>18</sup>F]-fluoromethylguanidine;

or a salt or solvate thereof.

6. (Previously presented) A compound according to claim 1, for use in an *in vivo* diagnostic or imaging method such as PET.

7. (Withdrawn) Use of a compound according to claim 1, in the manufacture of a radiopharmaceutical for the *in vivo* diagnosis or imaging of an NMDA-mediated disease.

8. (Withdrawn) A method for the *in vivo* diagnosis or imaging of NMDA-mediated disease in a subject, preferably a human, comprising administration of a compound according to claim 1.